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MUC1 is expressed by glandular epithelial cells. It is overexpressed in the majority of breast tumours, making it a potential target
for immune therapy. The objectives of the present study were to evaluate the anti-tumour activity and tolerance of repeated admin-
istration of TG1031 (an attenuated recombinant vaccinia virus containing sequences coding for human MUC1 and the immune
stimulatory cytokine IL-2) in patients with MUC1-positive metastatic breast cancer. This was an open-label, randomised study
comparing two dose levels, 5× 10E6 and 5× 10E7pfu, with 14 patients in each arm. The treatment was administered intramuscu-
larly every 3 weeks for the first 4 doses and every 6 weeks thereafter, until progression. Two patients had a partial tumour regression
(> 50%), and 15 patients had stable disease as their best overall response until at least the 5th injection. Partial regression lasted for
11 months in one patient and for 12 months in the second patient who then underwent surgical resection of her hepatic metastases.
The most frequent adverse events included inflammation at injection site: 7 patients, itching or pain at injection site: 5 patients, and
moderate fever: 6 patients. One responding patient developed antinuclear, anti-DNA, and increased anti-TPO antibodies after the
fifth injection, and which resolved at the end of treatment. The treatment regimes were well tolerated with a low toxicity profile.
Although clinical eﬃcacy remains limited, this study demonstrates the potential use of MUC1-based immune therapy in breast
cancer.
INTRODUCTION
Reversal of tolerance and induction of antitumour ac-
tivity has been shown following immunisation with fu-
sions of dendritic andMUC1-positive carcinoma cells [1],
and MUC1-positive CTL’s have been detected following
successful immunotherapy in renal cancer patients fol-
lowing administration of fused dendritic and renal cancer
cells [2]. Mucins are large (> 200 kd) glycoproteins with a
high carbohydrate content (50–90% by weight). They are
expressed by a variety of normal and malignant epithelial
cells. MUC1 has a small transmembrane and intracellu-
lar tail and consists essentially of a large number (30–100)
of repeated segments in tandem of 20 amino acids. The
peptide core is densely coated with oligosaccharides, con-
ferring a rigid rod-like structure which can extend sev-
eral hundred nanometers from the apical cell surface into
the lumen of ducts and glands. The biological function of
MUC1 is thought to lubricate and protect glandular ducts,
but knockout mice, lacking MUC1, had no alteration in
their development and in their glandular morphology [3].
Mucins are attractive tumour antigens as they are over-
expressed (10–40 fold) in a variety of cancers, making
them useful targets for antibodies and cellular immunity.
Cancer-associated MUC1 is incompletely glycosylated
and as a result exposes internal sugar units and naked
peptide sequences which are cryptic in the normal mucin
molecule. MUC1 glycoprotein is often found in circula-
tion in late-stage breast and lung cancer and used as a tu-
mour marker (CA15.3) in the follow-up of breast cancer
patients. Patients with high circulating MUC1 (CA153)
serum levels have advanced cancer and are frequently in a
state of T-cell unresponsiveness or anergy [4, 5]. Although
it had been suggested in the past that MUC1 caused T-
cell unresponsiveness, a direct immunosuppressive role
for MUC1 was excluded in more recent analyses [6].
The complete human MUC1 gene containing only 5
tandem repeats which had been inserted into a vaccinia
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virus vector, together with the gene coding for human
interleukin 2, has been tested in a prior phase I study.
A significant T-cell proliferative response against MUC1
following vaccination was observed in 1 of 9 advanced
metastatic breast cancer patients. The stimulation index
rose from 7 to 14 following a second injection. In addi-
tion, evidence of MUC1-specific CTL activity induced by
VV-MUC1-IL-2 was seen. The present study was designed
to expand on these earlier findings in metastatic breast
cancer patients vaccinated after only one line of systemic
treatment. Our objectives were to evaluate signs of clinical
eﬃcacy and tolerance of repeated injections as well as to
assess the cellular and humoral response to MUC1 given
at two diﬀerent dose levels.
PATIENTS ANDMETHODS
Patients
We intended to enrol 28 patients into the study,
14 in each treatment group. The study was approved
by each country’s regulatory authorities and by the lo-
cal ethical committees. The inclusion criteria were his-
tologically proven MUC1-positive breast cancer, pro-
gressive and measurable metastatic disease following no
more than one line of systemic treatment, WHO perfor-
mance index 0–1, and total lymphocyte counts greater
than 0.75 × 10E9/L. Principal exclusion criteria were
recent viral infection, positive serology for HIV, ma-
jor organ dysfunction, concomitant corticosteroid treat-
ment, evidence of immunological compromise such as
eczema or atopic dermatitis, and central nervous sys-
tem metastasis. MUC1 antigen expression by the tu-
mour was evaluated by immunohistochemistry using an-
tibody H23 [7] on paraﬃn-embedded sections. In France,
the immunological status of each patient was evaluated
by a Pasteur-Me´rieux multitest to recall antigens. Ad-
ditional evaluations included antibodies to DNA and
levels of serum amylase, β2-microglobulin, C-reactive
protein, total immunoglobulin levels, and CD4 : CD8
counts.
Preclinical toxicology
The human MUC1 and IL-2 cDNA were inserted
in a head-to-head orientation under the control of the
p7.5 promoter located at 5′ of each sequence. This block
was inserted into the vaccinia virus (Copenhagen strain)
genome. Previous results [8] demonstrated an attenua-
tion of the viral virulence by both the inactivation of the
viral TK as well as by the production of IL-2. Intracra-
nial injection of this construct into nude mice was non-
toxic, whereas injection of the parent strain was lethal in
all instances (Bizouarne et al [9]). Transgenic mice ex-
pressing human MUC1 under the control of the human
MUC1 promoter have been constructed and found to ex-
press MUC1 strongly and consistently in the cells lining
the stomach. These mice had been used to assess, both
histologically and macroscopically, any signs of autoim-
munity induced by immunisation with VV-MUC1-IL-2
(VVTG-5058, the active viral ingredient of TG1031). No
histological evidence of inflammatory cell infiltrate into
normal tissues expressing MUC1 was observed, nor was
there any gross evidence of autoimmune disease over a
period of twomonths observation. Immunisation of these
mice with MUC1 resulted in an anti-MUC1 antibody re-
sponse which was dramatically lower than that seen in
immunised nontransgenic mice, demonstrating a degree
of tolerance to MUC1 at the level of antibody produc-
tion. Nonetheless, MUC1-specific cytotoxic T lympho-
cyte precursor cells (CTL-pc) could be detected in both
transgenic and nontransgenic mice following immunisa-
tion with VVTG-5058 [10].
Production of IL-2 by VVTG-5058-infected cells was
measured both in vitro and in vivo. BHK-21 (baby ham-
ster kidney) cells were infected with VVTG-5058 and the
culture supernatant assessed for IL-2 both by ELISA and
by bioactivity using the cell line CTLL-2. After 24-hour
culture, the infected cells secretion of IL-2 ranging from
675 ng/ml to 1117 ng/ml and was equivalent to biologi-
cally active IL-2 ranging from 1283 to 8340 IU/ml. Con-
trol supernatants from cells infected with the negative
control wild-type virus contained no detectable IL-2. Pro-
duction of IL-2 in vivo was assessed by injecting DBA/2
mice intramuscularly with VVTG-5058 and assessing IL-2
in the serum at later time points. Only at the 24-hour time
point was IL-2 detectable at 50 pg/ml and it was thereafter
undetectable. Viral dose was assessed by plaque forming
activity on BHK cells.
Patientmonitoring
Informed consent was obtained from each patient. Pa-
tients remained in a hospital room with a confinement
compatible with HSE B2 specifications [11]. Patients were
monitored in this confined room following each admin-
istration: for 24 hours after the first injection and for 2
hours after subsequent injections. In France, patients re-
mained in this unit for 2 days on each occasion and un-
til blood samples and nasopharyngeal swabs, taken on
the day following the injection, were reported negative by
PCR analysis. Vaccination with 0.5ml of TG1031 (doses
of 5× 10E6 or 5× 10E7pfu) was done intramuscularly in
the deltoid muscle.
Viral monitoring (subgroup analysis)
Samples were assessed for the presence of infectious
vaccinia virus by PCR analysis at Texcell laboratories, In-
stitut Pasteur, Paris. Special care was taken to prevent viral
dissemination prior to and during transport. Swabs taken
from the nose and throat, as well as samples of blood,
were analysed prior to vaccination at day 0 and daily dur-
ing the hospitalisation period. The detection limit was 2–
9 pfu/ml in wet and 150 pfu/ml in dry samples. PCR anal-
ysis of virus was done with two pairs of primers designed
to amplify either a 1.2- kbp portion of a region of MUC1
with vaccinia flanking sequences or a second smaller re-
gion (740 bp) within MUC1.
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Vaccinia- andMUC1-specific serology
MUC1-specific IgG and IgM antibody levels were de-
tected by ELISA with microtitre plates coated with a BSA-
conjugatedMUC1 60mer peptide from the tandem repeat
sequence as previously described [12].
MUC1-specific proliferative responses by in vitro
stimulation of PBMCs
Ficoll/Hypaque separated peripheral blood mononu-
clear cells (PBMCs) were frozen in 10% DMSO. Collected
samples were thawed and tested for viability, and aliquots
were incubated in the presence of mitogens (PHA and
anti-CD3 monoclonal antibodies) and each antigen (hu-
man MUC1 from tandem repeat TAPPA-24 [13], mouse
MUC1, purified protein derivative (PPD), and vaccinia
virus) for 5 days. Cell proliferation is measured by the
incorporation of 3H-thyminidine into the cellular DNA.
Phytohemagglutinin (PHA), a mitogen which stimulates
all T cells by cross-linking several cell surface glycopro-
teins by virtue of their sugar side chains, was used as a
control. Another positive control mitogen, the anti-CD3
monoclonal antibody UCHT1, also was used.
Cytokine production (subgroup analysis)
Five hundred microlitre of the patients’ plasma
(lithium heparin) was aliquoted and stored at −20◦C.
All assays were carried out using commercial ELISA kits
(R&D, Minneapolis, Minn, USA) in duplicate samples
and in the same assay testing for VEGF, M-CSF, TNF-β1
as well as IL-6 and IL-10. Results are expressed in pg/ml.
RESULTS
Clinical summary
Thirty-one female patients with metastatic breast can-
cer positive forMUC1 antigen were enrolled between June
1998 and March 1999 in four centres. Fourteen patients
were randomised to the lower dose group (5 × 10E6pfu)
and 17 patients to the higher dose group (5 × 10E7pfu).
The patients’ mean age was 56.3 years (ranging from 33
to 76 years), and the mean ECOG performance status at
baseline 0.2 (ranging from 0 to 1).
Eight patients (26%) had one metastatic site (3 pa-
tients 5 × 10E6pfu, 5 patients 5 × 10E7pfu); 18 pa-
tients (58%) had 2–3 metastatic sites (7 patients 5 ×
10E6pfu, 11 patients 5 × 10E7pfu); and 5 patients had
more than 3 metastatic sites (4 patients 5 × 10E6pfu,
1 patient 5 × 10E7pfu). All patients had received pre-
vious therapy for their metastatic breast cancer, includ-
ing antioestrogens (24 patients), Goserelin (1), aromatase
inhibitors (10), anthracyclines [alone (8) or in combina-
tion with (FEC/FAC) (9)], Taxotere/Taxol (8), 5FU-based
chemotherapy (8), MMM (2), and Navelbine (4). One pa-
tient (patient 106, 5× 10E7pfu group) had received prior
immunotherapy. Patients received a median number of 3
cycles (ranging from 2 to 8) of drug treatment during the
study [5 × 10E6pfu group: median of 4 cycles (ranging
Table 1. Tumor measurements in patient 207.
Liver lesion January 11 March 3 May 7 August 6
Segment VII 19× 19 18× 18 16× 16 11× 11
Segment VI 28× 24 28× 22 26× 22 19× 19
Cupole 20× 20 15× 20 12× 14 4× 4
from 2 to 7) and 5 × 10E7pfu group: median of 3 cycles
(ranging from 2 to 8)].
Efficacy analysis
Two out of 31 (6%) patients achieved a partial re-
sponse (PR), 1 in each treatment group. No complete re-
sponse was seen. Stable disease (SD) was the best over-
all response observed in 15 (48%) patients (7 in the 5 ×
10E6pfu group and 8 in the 5× 10E7pfu group).
Patient 207 (5×10E6pfu treatment group) was treated
for over 1 year (11 cycles) with PR then SD first detected
on day 148. She had a surgical resection of the remain-
ing liver metastases and was free of disease at the time of
analysis, 18months after the start of vaccination (Table 1).
Patient 204 (5×10E7pfu treatment group) was treated for
9 cycles, showing a PR on day 103, and remains stable at
11 months of treatment. This patient’s tumour regressed
subsequently with perfusion chemotherapy.
Time to progression
The median time to progression in the 5 × 10E6pfu
group was 91 days (95% confidence interval (CI): 35 to
105 days), compared to 59 days (95% CI: 38 to 81 days) in
the 5 × 10E7pfu group (NS). A total of 7 patients (23%)
died, one (patient 109, 5×10E6pfu group) because of pro-
gressive disease during the course of the study, 5 weeks af-
ter the start of treatment. Six patients died of progressive
disease during the follow-up period, defined as more than
28 days after last injection (1 in the 5×10E6pfu group and
5 in the 5× 10E7pfu group).
Safety
All the 31 patients enrolled in the study were included
in the safety analysis. The administration of TG1031 was
generally well tolerated. All patients experienced at least
one adverse event. Adverse events were considered as
treatment-related in 22/31 (71%) of patients (5×10E6pfu
group: 9 patients; 5 × 10E7pfu group: 13 patients). The
most frequently reported adverse events were general dis-
orders and reactions at the injection site in 23/31 (74%) of
patients (5× 10E6pfu group: 8 patients and 5× 10E7pfu
group: 15 patients) followed by gastrointestinal disorders
in 15 patients (5×10E6pfu group: 7 patients; 5×10E7pfu
group: 8 patients) and musculoskeletal and bone dis-
orders in 14 patients (5 × 10E6pfu group: 6 patients;
5× 10E7pfu group: 8 patients). Only one patient (patient
305, 5× 10E7pfu group) had a grade-3 fatigue which was
considered as probably drug-related and which resolved
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within 14 days. Five patients reported serious adverse
events (5×10E6pfu group: 2 patients; 5×10E7pfu group:
3 patients) that were considered unrelated to study medi-
cation (5 × 10E6pfu group: 2 patients had dyspnoea and
worsening of preexisting dyspnoea; 5 × 10E7pfu group:
3 patients had vaginal haemorrhage/anaemia, worsening
of preexisting dyspnoea, and fever—due to indwelling
catheter). None of the NCIC-CTC (National Cancer In-
stitute of Canada-Common Toxicity Criteria) grade 3/4
abnormal laboratory values were considered clinically sig-
nificant.
Viral dissemination
Tests for viral dissemination were carried out as de-
scribed in material and methods. All viral tests were con-
sistently negative.
Biological results
T-cell proliferation assays
Cellular immune response to the vector
Cellular immune responses were measured by cultur-
ing patients’ PBMCs together with one of a panel of sev-
eral antigens and mitogens. For all patients, the PBMCs
responded normally to UCHT1, an anti-CD3 antibody.
PPD from the tuberculin bacillus was used as a positive
control antigen. Most Europeans have been immunised
with tuberculin during their lifetime and most patients’
PBMCs responded normally to PPD, with some varia-
tion throughout the study. Reactivity to UV-inactivated
VV particles was equally assessed. Despite the fact that
most, if not all patients, had received smallpox vaccina-
tions during their lifetime, PBMCs from only one patient
(patient 106) showed T-cell proliferation to VV at base-
line. PBMCs from most, but not all patients, proliferated
in response to culture with VV at the second and subse-
quent injection time points. There was a significant vari-
ability in the condition of the cells and their ability to
proliferate in response to antigen. Negative controls were
either no antigen at all or MUC1 tandem repeat peptide
from the murine MUC1 sequence, which has little or no
cross-reactivity with human MUC1.
Cellular immune response toMUC1
None of the PBMCs from patients in this study
showed any significant T-cell proliferation in response to
a 24-amino acid polypeptide corresponding to oneMUC1
variable-number tandem repeat sequence. Nevertheless,
PBMCs from patients 207 and 208, for example, at some
time points were able to respond to both PPD and VV
antigens without evidence of proliferation in response to
the MUC1 antigen by the same PBMCs. The interpreta-
tion, therefore, is that there was no evident systemic T-
cell response to the tandem repeat (TAPPA 24) peptide of
MUC1 by PBMCs from the patients in this study as de-
tected by this method.
Vaccinia-andMUC1-specific antibodies
Antibody responses to the vector (vaccinia virus)
Most patients showed evidence of preexisting anti-
body immunity to vaccinia virus. All patients showed in-
creased anti-VV titres after vaccination, with the excep-
tion of patient 202 who had a comparatively high VV-
specific IgG titre in her pre-inclusion plasma sample,
which did not change throughout the course of TG1031
vaccinations, of which she received six. This suggests that
the patient had received a smallpox vaccination, but failed
to generate a recall response to TG1031. The most pro-
nounced rise in titre occurred in those patients receiving
the highest dose.
Antibody responses toMUC1
The analysis of MUC1-specific antibody titres was
performed according to a published method [14]. There
was no significant antibody response to MUC1 upon im-
munotherapy with TG1031, and levels of antibody did not
exceed levels found in some cancer patients. There were
few notable fluctuations: MUC1-specific IgG levels in
plasma from patient 104 dropped to 50% of pretreatment
levels at cycles 4 and 5 then increased to levels slightly
higher than baseline in subsequent samples. This was not
thought to be related to levels of complex formation with
circulating MUC1, since CA-15.3 levels increased only
slightly in this patient and remained within the normal
range. A similar phenomenon had been observed in one
patient in the VV-MUC1-IL-2 phase I clinical trial. Small
increases of IgG MUC1-specific antibody titres were de-
tected in four patients, including the clinical responders.
CD4 levels and outcome (subgroup analysis)
In view of the reported absence of toxicity in animal
studies and the reported attenuation by viral TK inactiva-
tion [15] and local IL-2 production [16], no restrictions
on inclusion by number of CD4+ lymphocyte counts had
been planned and this information is only available from
the subgroup analysis in France. CD4 counts immediately
preceding vaccinations were consistently above 600 in 4
patients including the 2 partial responders, reaching val-
ues as high as 1400 counts/mm3 after several injections
while CD4 levels in patients with rapidly progressive dis-
ease were low at baseline and did not increase after several
injections (Figure 1).
Cytokine plasma levels (subgroup analysis)
Cytokines that have repeatedly been associated with
immune suppression or defective dendritic cell diﬀerenti-
ation are shown in Figure 1 and Table 2.
Prevaccination M-CSF levels were the highest (669
and 957 pg/ml) in patients 203 and 206 who progressed
early and the lowest (235 and 246 pg/ml) in patients 204
and 207 who developed a clinical response. ELISA assays
using the same kit in over 600 primary breast cancers
prior to treatment had shownmedian values of 380 pg/ml.
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(a) Patients with baseline high CD4 and low M-CSF levels: PR in
patients 204 and 207.
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(b) Patients with baseline low CD4 and/or high M-CSF levels.
Figure 1
Both patients who showed a partial clinical response had
consistently low M-CSF levels and high CD4 counts. No
specific patterns in other serum cytokines (IL-10, TGFb1,
or VEGF) were detected.
Autoimmunity
Signs of autoimmunity were detected in 3 out of 10
patients following either routine screening for anti-DNA
antibodies (patient 207), following subsequent retrospec-
tive screening for anti-TPO (thyro-peroxidase) antibodies
(patients 205 and 207), or following biopsy of accessory
salivary gland for dry mouth (patient 209).
Patient 207, who showed the best response to study
treatment, developed high titres of anti-DNA antibodies
(up to 15U/ml after 6 injections) and raised anti-TPO
Table 2. Immunosuppressive cytokines.
VEGF TGF b1 rec IL-10
1 base line 0 434 0
3 21 338 0
5 54 1610 0
2 base line 143 326 0
3 216 1520 0
4 41 572 0
6 342 170 0
3 base line 173 644 0
1 39 2402 0
2 66 1256 0
3 41 506 0
4 base line 136 2450 0
3 301 164 0
5 78 548 0
8 328 2678 0
5 base line 738 440 0
3 236 6170 0
6 3 187 950 0
end 276 692 57
7 base line 43 164 0
3 36 836 0
4 72 2408 0
8 218 962 0
8 base line 44 272 0
3 10 266 0
5 9 482 0
9 3 20 272 0
10 base line 30 266 0
2 85 1628 0
antibodies (baseline: 179U/ml; extremes: 11529U/ml af-
ter the 8th injection down to 1438U/ml five months after
the 10th injection for a normal range < 60U/ml). Cir-
culating CD4 lymphocyte numbers doubled prior to the
third injection, peaking at 1444×106/L at the 8th injection
(CD4/CD8 ratio: 5.5) at a time point consistent with a re-
sponse to treatment (Table 3). Thyroid function tests were
subnormal in one occasion (after the 8th injection) to re-
turn to the normal range within 3 weeks. The patient had
no clinical signs of thyroid insuﬃciency. Renewed ques-
tioning revealed a family history of thyroid disorder. One
sister also had breast cancer. These biological signs of au-
toimmunity spontaneously resolved while the patient was
still being treated.
DISCUSSION
The use of vaccinia virus as a carrier and an adjuvant
for overexpressed tumour antigens has been reported in
a number of phase I trials in a variety of patients with
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Table 3. Variations of CD4 levels and antithyroid antibodies over the course of treatment in patient 207.
injection # date CD4 CD4/CD8 CA153 anti-TPO anti-nuclear anti-DNA T4 TSH
counts/mm3 ratio U/ml U/ml Inverse ratio U/ml ng/L µU/ml
BL 20/01/99 680 26 179 0 0
1 28/01/99 23 0 0 10.7 1.18
2 18/02/99 908 18 0 0 10.3 1.94
3 11/03/99 1160 4.7 18 0 0
4 01/04/99 1081 5.2 17 0 0
5 17/05/99 1172 5.6 16 0 0 12 2.92
6 28/06/99 1305 18 80 14 15.2 2.23
7 09/08/99 1224 4.7 17 160 15
8 20/09/99 1444 5.5 18 11529 320 13 5.8 51.29
9 02/11/99 1345 3.5 18 11052 11.9 9.14
10 13/12/99 966 4.7 18 6667 260 7 12 0.97
solid tumours such as breast, prostate, and cervical cancer
[17, 18, 19]. Vaccinations of wild life against rabies have
shown vaccinia virus to be eﬀective and safe for the en-
vironment [20]. Nonpathogenic viruses for humans, such
as fowl pox viruses, are also used in vaccination trials and
have been shown to increase the eﬃcacy of boost injec-
tions in alternate prime and boost strategies using dif-
ferent vectors with diﬀerent antigenic epitopes [12]. We
have developed a recombinant vaccinia virus, replicative
but attenuated, that expresses upon infection the widely
overexpressed breast cancer antigen MUC1 as well as the
human immunostimulatory cytokine IL-2. We have been
able to confirm the safety and eﬃcacy of repeated in-
jections of the same vector as well as provide clinical
evidence of vaccine eﬃcacy in metastatic breast cancer
patients.
In the present phase II study, repeated injections of
this vector in patients with less advanced disease gener-
ated clinical regressions of axillary lymph nodes (seen af-
ter 1 injection) and of liver metastases (after 3 injections)
(Figure 1). Increasing evidence exists from murine, pri-
mate, and human studies to confirm that T-cell prolif-
erative responses as well as MHC-restricted cytotoxic T
cells can be induced by immunisation with MUC1 anti-
genic epitopes [4, 21, 22, 23, 24, 25, 26, 27, 28]. In the
present study, no specific proliferative response directed
against an epitope of the human MUC1 tandem repeat
domain could be detected in any of our patients. Although
with the same assay T-cell proliferation was seen in a
previous trial [3], the proof of treatment-related MUC1-
specific systemic cellular immune responses could not
so far be confirmed in the present patients by in vitro
testing. The recent demonstration of class I HLA-A2 re-
stricted epitopes derived from the MUC-1 tandem re-
peat region or from the leader sequence of MUC-1 sug-
gests that the MUC-1-directed immune responses may
not be limited to the extracellular tandem repeat domain
[26]. Using peptide-pulsed dendritic cells in addition to
Pan-HLA-DR binding peptides, Brossart et al [26] also
demonstrated the importance of CD4 cells for eﬃcient
CTL priming. It remains to be seen whether the patients
who demonstrated a clinical response developed CTL’s
or a proliferative response against other epitopes that we
have not yet tested for. Murine experiments have shown
that immunisation withMUC1 without tandem repeats is
as eﬀective as immunisation with the entire MUC1 in in-
ducing a tumour rejecting anti-MUC1 immune response
(Taylor-Papadimitriou et al [29]). In addition and in a
separate study, several patients immunised with MUC1
showed T-cell proliferative responses to MUC1 antigenic
epitopes outside the tandem repeat region (Rochlitz et al
[30]).
All but one patient had serological evidence of vac-
cination with vaccinia virus in childhood. Antibodies
against the virus were detectable prior to vaccination, and
patients treated with the highest dose levels had increased
serological responses to vaccinia virus, but surprisingly
little response to MUC1. Our results are in contrast with
those of Apostolopoulos et al [30] who document a pre-
dominant antibody response following serial vaccinations
with a peptide-mannan fusion protein. High titres of an-
tibodies to MUC1 in MUC1-immunised patients are pos-
sible, as reported by other clinical trials in which patients
had been immunised with polypeptides from the MUC1
tandem repeat sequence [31]. Antibody, but not T-cell tol-
erance to MUC1 has been observed in MUC1 transgenic
mice immunised with vaccinia-MUC1-IL-2 [10]. It is not
clear whether antibodies may give equivalent antitumour
protection to that of a cellular immune response. A benefit
in survival has been observed in early-stage breast cancer
patients with elevated natural antibodies to MUC1 [20].
Similarly, an increase in antibody titres has been reported
in multiparous women [13], and Agrawal et al specu-
lated that the well-known decreased breast cancer risk in
women having pregnancies early in their reproductive life
might be related to spontaneous vaccination against this
breast tumour antigen. Only one patient (number 301)
injected with VV-MUC1-IL-2 had a notable antibody titre
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to MUC1 prior to vaccination and maintained signifi-
cant titres of IgM anti-MUC1 antibodies following vacci-
nation. Vaccination using the complete MUC1 gene and
therefore the presentation of a variety of MUC1 class I
or II epitopes in the context of a viral expression vector
may also influence the type (cellular or humoral) of re-
sponse.
We did not observe any virus-related toxicity, nor did
we detect any viral particles by PCR technology, suggest-
ing that the repetitive viral injection was safe. Antiviral an-
tibodies were present and increased mildly during treat-
ment.
In a subgroup analysis, a rise in circulating (non-
specified) CD4 T lymphocyte counts was seen in some
patients, and in particular, in the two responding pa-
tients suggestive of that the immune system still sus-
ceptible to stimulation. These results compare with ob-
servations from the literature showing a correlation be-
tween high level of circulating CD4+ lymphocytes and
the favourable outcome. Recent evidence from a hu-
man melanoma model suggested that the true bene-
fit of CD4+ T cells may be not only in the induction
and maintenance of cytotoxic T lymphocytes, but pos-
sibly in a direct (CD4-mediated) antitumour response
[33]. Low levels of immune-suppressive cytokines such
as M-CSF, TGFβ1, IL-6, VEGF, and low C-reactive pro-
tein had been seen in those patients able to develop CTL’s
against MUC1 following vaccination in the past [23].
High amounts of M-CSF, VEGF, and IL-6 in tumour
cell supernatants have been associated with suppression
of dendritic cell diﬀerentiation [34, 35] as well as with
tumour progression. Tumour-generated suppressive fac-
tors may thus represent a limiting factor to immunother-
apy. In primary breast carcinomas, Bell et al did detect
only immature dendritic cells within the tumour, whereas
mature dendritic cells were located in peritumoral areas
[36].
In the same subgroup, several low-grade autoim-
mune manifestations were documented in 3 of 10 pa-
tients. The rise in self antibodies was parallel to the
rise in peripheral CD4 cells and to the clinical response
in one patient. The presence of inflammatory cells in
a biopsy of accessory salivary glands was seen in one
patient who had complained of dry mouth following
injection. Autoimmune reactions have also been docu-
mented in renal cell cancers following treatment with
IL-2 [37]. The patients with signs of antithyroid an-
tibodies had a significantly better survival, suggesting
that a mild degree of autoimmunity may be a positive
sign more than an “acceptable side eﬀect” of antitumour
vaccinations.
In conclusion, multiple injections of VV-MUC1-IL-2
were clinically well tolerated and able to induce clinical
responses in two patients. Mild autoimmune eﬀects were
present in some patients, including one of the clinical re-
sponders. We suggest monitoring peripheral CD4 titres
and autoantibodies in future trials.
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